))
The synergy solution: How public-private partnerships advance regenerative medicine
Manage episode 389567675 series 3291201
Content provided by CCRM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CCRM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring:
Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult
Michael May, PhD, President and Chief Executive Officer, CCRM
***
Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President and CEO, CCRM, explain how these collaborations have had an impact in the regenerative medicine sector by advancing cell and gene therapies along the commercialization pathway. Our guests share highlights from their organizations, including the types of partners they have worked with, and the infrastructure and facilities they have helped to create.
The interview concludes with a discussion of how public-private partnerships will benefit patients in the future by improving the factors that lead to market access and adoption, such as developing markets, promoting acceptability, reducing the cost of goods, and enabling the supply chain.
Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.
18 episodes
Share
